Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OTC | P00480 | 1/20 | 0.49 |
| ▸ | NOS3 | P29474 | 4/20 | 0.44 |
| ▸ | NOS1 | P29475 | 4/20 | 0.44 |
| ▸ | NOS2 | P35228 | 4/20 | 0.44 |
| ▸ | DDAH1 | O94760 | 1/20 | 0.43 |
| ▸ | NOD1 | Q9Y239 | 2/20 | 0.42 |
| ▸ | GSR | P00390 | 1/20 | 0.42 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | ARG2 | P78540 | 4/20 | 0.39 |
| ▸ | ARG1 | P05089 | 3/20 | 0.39 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1345201 | 0.90 | PMP22 (0.41) | OTCNOS3NOS1NOS2GSR | |
| SCHEMBL5246763 | 0.90 | PMP22 (0.41) | OTCNOS3NOS1NOS2GSR | |
| Tilarginine SCHEMBL6370536 | 0.83 | OTC (0.51) | OTCNOS3NOS1NOS2DDAH1 | |
| Tilarginine SCHEMBL315843 | 0.83 | OTC (0.51) | OTCNOS3NOS1NOS2DDAH1 | |
| Tilarginine SCHEMBL12028766 | 0.83 | OTC (0.51) | OTCNOS3NOS1NOS2DDAH1 | |
| SCHEMBL19670848 | 0.83 | DPP7 (0.36) | OTCDPP7MEN1KMT2A | |
| SCHEMBL30544568 | 0.83 | OTC (0.48) | OTCNOS3NOS1NOS2DDAH1 | |
| SCHEMBL1004634 | 0.82 | OTC (0.50) | OTCNOS3NOS1NOS2DDAH1 | |
| SCHEMBL21089975 | 0.82 | OTC (0.50) | OTCNOS3NOS1NOS2DDAH1 | |
| SCHEMBL12028765 | 0.82 | OTC (0.50) | OTCNOS3NOS1NOS2DDAH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220162156-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME | Cellix Bio Provate Limited (IN) | 2022-05-26 | — | — | US | disclosed |
| US-11078154-B2 | Compositions and methods for the treatment of irritable bowel syndrome | CELLIX BIO PRIVATE LIMITED (IN) | 2021-08-03 | — | — | US | disclosed |
| US-20190177267-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME | CELLIX BIO PRIVATE LIMITED (IN) | 2019-06-13 | — | — | US | disclosed |
| US-9988340-B2 | Compositions and methods for the treatment of multiple sclerosis | CELLIX BIO PRIVATE LIMITED (IN) | 2018-06-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220162156-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME | SI, SLC10A2, F5 | OTC 2436/4885NOS3 973/4885NOS1 1845/4885 |
| US-11078154-B2 | Compositions and methods for the treatment of irritable bowel syndrome | SI, SLC10A2, ALPI | OTC 1129/4885NOS3 558/4885NOS1 608/4885 |
| US-20190177267-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME | SI, SLC10A2, F5 | OTC 2436/4885NOS3 973/4885NOS1 1845/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.